224 related articles for article (PubMed ID: 10708300)
1. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors.
Janson ET; Kälkner KM; Eriksson B; Westlin JE; Oberg K
Nucl Med Biol; 1999 Nov; 26(8):877-82. PubMed ID: 10708300
[TBL] [Abstract][Full Text] [Related]
2. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
3. Radio-guided surgery in neuroendocrine tumors.
Gulec SA; Baum R
J Surg Oncol; 2007 Sep; 96(4):309-15. PubMed ID: 17726664
[TBL] [Abstract][Full Text] [Related]
4. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.
Dörr U; Wurm K; Höring E; Guzman G; Räth U; Bihl H
Horm Metab Res Suppl; 1993; 27():36-43. PubMed ID: 8330870
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor imaging in intracranial tumours.
Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview.
Kwekkeboom DJ; Krenning EP
Eur Radiol; 1997; 7(7):1103-9. PubMed ID: 9265684
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor imaging in patients with neuroendocrine tumors: preoperative and postoperative scintigraphy and intraoperative use of a scintillation detector.
Ahlman H; Tisell LE; Wängberg B; Nilsson O; Forssell-Aronsson E; Fjälling M
Semin Oncol; 1994 Oct; 21(5 Suppl 13):21-8. PubMed ID: 7992076
[No Abstract] [Full Text] [Related]
10. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
[TBL] [Abstract][Full Text] [Related]
11. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
Pauwels S; Leners N; Fiasse R; Jamar F
Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
[No Abstract] [Full Text] [Related]
12. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results.
Krenning EP; Kwekkeboom DJ; Oei HY; de Jong RJ; Dop FJ; Reubi JC; Lamberts SW
Ann N Y Acad Sci; 1994 Sep; 733():416-24. PubMed ID: 7978890
[No Abstract] [Full Text] [Related]
13. Peptide receptor imaging and therapy.
Kwekkeboom D; Krenning EP; de Jong M
J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
[TBL] [Abstract][Full Text] [Related]
14. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
[TBL] [Abstract][Full Text] [Related]
15. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
[No Abstract] [Full Text] [Related]
16. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S
Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227
[TBL] [Abstract][Full Text] [Related]
17. In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex.
Lukinius A; Ohrvall U; Westlin JE; Oberg K; Tiensuu Janson E
Acta Oncol; 1999; 38(3):383-7. PubMed ID: 10380832
[TBL] [Abstract][Full Text] [Related]
18. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
[TBL] [Abstract][Full Text] [Related]
19. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
Slooter GD; Mearadji A; Breeman WA; Marquet RL; de Jong M; Krenning EP; van Eijck CH
Br J Surg; 2001 Jan; 88(1):31-40. PubMed ID: 11136306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
